New drug could soon thwart smallpox outbreaks
A smallpox pill could help stem an outbreak quickly.
An anti-smallpox pill could be on the way if a new compound that shows promise in animal tests proves safe and effective in humans. Such a pill could provide the best method for controlling an unforeseen smallpox outbreak, its developers claim.
The need for new ways to treat smallpox has only become an issue in recent years as the threat of a deliberate release of the virus intensifies. Smallpox - a highly contagious and often lethal viral disease - was officially eradicated by vaccination in 1979.
"We disguised cidofovir so the body thinks its a dietary fat," Hostetler explains. His team attached to cidofivirs active component a molecule called lecithin, a breakdown product of fat found in all foods. This Trojan horse approach tricks the body into absorbing the drug and carrying it to where it is needed.
Small doses of the new compound - called HDP-CDV - killed the virus in smallpox-infected cells. "The big surprise was that its antiviral activity went up 100-fold compared to cidofovir," says Hostetler.
A single, daily dose of the drug also cured mice of cowpox, Huggins found. Untreated mice died within days.
Whats more, cowpox was undetectable in the respiratory tracts of mice treated with HDP-CDV. Because smallpox is spread by infectious droplets that are coughed up, this finding suggests that HDP-CDV might help to stem an epidemic.
These early tests raise hope that HDP-CDV might be incorporated into an anti-smallpox pill that could be distributed widely without the need for public-health workers to administer it, says Hostetler.
"But there is tons of work left to do," he warns. Even though the new compound is based on an existing drug, it must undergo the same rigorous testing as any other. The team dont expect that process to begin for at least another year.
The possibility of an effective drug for smallpox is likely to fuel the debate among smallpox experts about the best way to control a future outbreak. Many prominent scientists argue that antiviral drugs such as cidofivir shouldnt play a prominent role.
Antivirals may save lives and perhaps reduce transmission, but they do not confer immunity to the disease, as vaccines do, the argument goes.
Donald Henderson, head of George W. Bushs newly created Office of Public Health Preparedness, is a prominent sceptic. The use of cidofovir "would be limited to administration at or shortly after infection had occurred to prevent the virus from multiplying and eventually causing disease", he says.
Antiviral drugs would best be used to treat people who cant be vaccinated, says Henderson. Those with weak immune systems can suffer adverse, even fatal, reactions to smallpox vaccine.
Joseph Esposito, a poxvirus specialist at the US Centers for Disease Control and Prevention in Atlanta, Georgia, agrees: "A new drug would be very important." But in terms of a national strategy, "the first line of defence is a proven one, and thats vaccination," he says.
But while questions loom about the number of smallpox vaccine doses available to limit an outbreak, and about the possibility of a smallpox virus being engineered that can outwit existing vaccines, antivirals deserve a fair trail, says Hostetler.
TOM CLARKE | © Nature News Service
Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center
Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
18.01.2018 | Life Sciences
18.01.2018 | Life Sciences
18.01.2018 | Earth Sciences